Table 1. Patient characteristics.
| N=22 | % | |
|---|---|---|
|
Age (years) | ||
| Median | 71 | |
| Range |
59–84 |
|
|
Race | ||
| White |
22 |
100% |
|
ECOG PS | ||
| 0 | 6 | 27.3% |
| 1 |
16 |
72.7% |
|
Gleason score | ||
| ⩾8 | 12 | 54.5% |
| 7 | 5 | 22.7% |
| ⩽6 | 3 | 13.6% |
| NA |
2 |
9.0% |
|
Metastatic sites | ||
| Bone | 18 | 82% |
| Lymph node | 17 | 77% |
| Visceral |
7 |
32% |
|
Prior treatment | ||
| Antiandrogen | 22 | 100% |
| LHRH analogue or antagonist | 22 | 100% |
| Docetaxel | 8 | 36.3% |
| Corticosteroids | 8 | 36.3% |
| Ketoconazole | 4 | 18.2% |
| Abiraterone | 3 | 13.6% |
| Other cytotoxics | 5 | 22.7% |
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group Performance status; LHRH=luteinizing-hormone-releasing hormone; NA= not applicable.
Other cytotoxic treatments: vinblastine (n=1), tesetaxel (n=1), cabazitaxel (n=2), taxol and carboplatin (n=1).